{
    "clinical_study": {
        "@rank": "50181", 
        "arm_group": {
            "arm_group_label": "BVD-523", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, multi-center Phase 1/2 study will assess the safety, pharmacokinetics, and\n      pharmacodynamics of escalating doses of BVD-523 in patients with advanced malignancies.  The\n      study also seeks to demonstrate target modulation and early signs of clinical response in\n      select patient populations."
        }, 
        "brief_title": "Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Solid Tumors", 
        "detailed_description": {
            "textblock": "The study is being performed to assess the safety and tolerability of BVD-523 given orally,\n      twice daily for 21-day cycles.\n\n      In Part 1 of the study, an accelerated dose escalation plan will be used to establish dose\n      limiting toxicities (DLT), maximum tolerated dose (MTD), and the recommended Phase 2 dose\n      (RP2D).\n\n      In Part 2 of the study, additional patients with particular tumor types and/or cancers\n      harboring specific genetic mutations will be recruited for treatment at the Recommended\n      Phase 2 Dose (RP2D). Patients may also be assessed pharmacodynamic measures in healthy or\n      malignant tissues, using biomarker assays for phosphorylation, cytotoxic or cytostatic\n      measures."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with metastatic or advanced-stage malignant tumor, confirmed histologically,\n             for whom no therapy exists that would be curative. Patients may have received up to 2\n             prior lines of chemotherapy for their metastatic disease.\n\n          -  ECOG performance status of 0 or 1\n\n          -  Predicted life expectancy of \u2265 3 months\n\n          -  Adequate bone marrow, liver and renal function renal function as assessed by the\n             following laboratory requirements:\n\n               1. creatinine \u2264 1.5 times ULN (upper limit of normal)] and/or GFR of \u2265 50mL/min\n\n               2. total bilirubin \u2264 1.5 x UNL; AST (aspartate transaminase) and/or ALT (alanine\n                  transaminase) \u2264   3x UNL or \u2264 5 x UNL if due to liver involvement by tumor\n\n               3. hemoglobin \u2265 9.0 g/dL; platelets \u2265 100 x 10 cells/L; absolute neutrophil count \u2265\n                  1.5 x 109 cells/L\n\n          -  Adequate cardiac function, e.g. [left ventricular ejection fraction (LVEF) of > 50%;\n             corrected QT interval (QTc) < 470 ms]\n\n          -  For women: Negative pregnancy test for females of child-bearing potential; must be\n             surgically sterile, postmenopausal, or compliant with a contraceptive regimen during\n             and for 3 months after the treatment period.\n\n          -  For men: Must be surgically sterile, or compliant with a contraceptive regimen during\n             and for 3 months after the treatment period.\n\n          -  For Part 2 of the Study ONLY patients must have measurable disease by RECIST 1.1 and\n             be in one of the following 4 groups:\n\n               1. Patients with BRAF mutated melanoma; not previously treated with inhibitors of\n                  BRAF, MEK, or ERK\n\n               2. Patients with BRAF mutated melanoma who have progressed while being treated with\n                  BRAF inhibitors.\n\n               3. Patients with BRAF mutated non-melanoma; not previously treated with inhibitors\n                  of BRAF, MEK, or ERK\n\n               4. Patients with RAS mutated advanced malignancy; not previously treated with\n                  inhibitors of BRAF, MEK, or ERK\n\n        Exclusion Criteria:\n\n          -  Gastrointestinal (GI) condition which could impair absorption of study medication\n\n          -  Uncontrolled or severe intercurrent medical condition\n\n          -  Known uncontrolled brain metastases. Stable brain metastases either treated or being\n             treated with a stable dose of steroids/anticonvulsants, with no dose change in the\n             previous 4 weeks, can be allowed\n\n          -  Any cancer-directed therapy (chemotherapy, radiotherapy, hormonal therapy, biologic\n             or immunotherapy, etc.) within 28 days or 5 half-lives, whichever is shorter\n\n          -  Major surgery within 4 weeks prior to first dose\n\n          -  Any use of an investigational drug within 28 days or 5 half-lives (whichever is\n             shorter) prior to the first dose of BVD-523. A minimum of 10 days between termination\n             of the investigational drug and administration of BVD-523 is required. In addition,\n             any drug- related toxicity except alopecia should have recovered to Grade 1 or less\n\n          -  Pregnant or breast-feeding women\n\n          -  Any evidence of serious active infections\n\n          -  Any important medical illness or abnormal laboratory finding that would increase the\n             risk of participating in this study\n\n          -  A history or current evidence/risk of retinal vein occlusion (RVO) or central serous\n             retinopathy (CSR)\n\n          -  Concurrent therapy with any other investigational agent\n\n          -  Concurrent therapy with drugs known to be strong inhibitors of CYP1A2, CYP2D6, or\n             CYP3A4, or strong inducers of CYP3A4."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01781429", 
            "org_study_id": "BVD-523-01", 
            "secondary_id": "BVD-523-01"
        }, 
        "intervention": {
            "arm_group_label": "BVD-523", 
            "description": "Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle", 
            "intervention_name": "BVD-523", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 31, 2014", 
        "location": [
            {
                "contact": {
                    "email": "zpwu@mednet.ucla.edu", 
                    "last_name": "Phyllis Wu", 
                    "phone": "310-794-0738"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "UCLA Med-Hematology & Oncology"
                }, 
                "investigator": [
                    {
                        "last_name": "Antoni Ribas, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Deborah Wong, M.D., Ph.D.", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "matthew.madura@yale.edu", 
                    "last_name": "Matthew Madura", 
                    "phone": "203-737-5381"
                }, 
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520"
                    }, 
                    "name": "Sarah Cannon Research Institute/Yale Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Paul Eder, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jimartin@flcancer.com", 
                    "last_name": "Jill Martin, RN", 
                    "phone": "941-377-9993", 
                    "phone_ext": "319"
                }, 
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34232"
                    }, 
                    "name": "Florida Cancer Specialists and Research Group (Sarah Cannon Research Institute)"
                }, 
                "investigator": {
                    "last_name": "Manish Patel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dmartinez7@partners.org", 
                    "last_name": "Dennise Martinez", 
                    "phone": "617-724-0695"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital (MGH)"
                }, 
                "investigator": {
                    "last_name": "Keith Flaherty, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Suzanne.jones@scresearch.net", 
                    "last_name": "Suzanne Jones, PhD", 
                    "phone": "615-329-7274"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute Hospital at Vanderbilt"
                }, 
                "investigator": [
                    {
                        "last_name": "Jeffrey Infante, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Howard Burris, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies", 
        "other_outcome": [
            {
                "description": "To evaluate pharmacodynamic measures in healthy or malignant tissues, using biomarker assays for phosphorylation, cytotoxic or cytostatic measures.", 
                "measure": "Pharmacodynamic response assessed by blood and tissue analyses.", 
                "safety_issue": "No", 
                "time_frame": "Patients will be evaluated at baseline and on ~day 15 of Cycle 1"
            }, 
            {
                "measure": "Radiographic response assessed using using F-fluorodeoxyglucose-positron-emission tomography (FDG-PET) scans.", 
                "safety_issue": "No", 
                "time_frame": "Patients will be evaluated at baseline and day 22 (end of 1st cycle) to identify early response."
            }
        ], 
        "overall_contact": {
            "email": "ssaha@biomed-valley.com", 
            "last_name": "Saurabh Saha, MD, PhD", 
            "phone": "816-960-4661"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Determination of recommended phase 2 dose (RP2D) of BVD-523 determined by dose-limiting toxicities.", 
            "safety_issue": "Yes", 
            "time_frame": "Until safety and tolerability limit further dose escalation; up to ~18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01781429"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Characterization of the time versus plasma concentration profiles of BVD-523 and selected metabolites.", 
                "safety_issue": "No", 
                "time_frame": "Samples will be collected on day 1 and day 15 of Cycle 1"
            }, 
            {
                "measure": "Clinical evidence of tumor response assessed by physical or radiological exam.", 
                "safety_issue": "No", 
                "time_frame": "Patients will be evaluated at baseline and at 60 days"
            }
        ], 
        "source": "BioMed Valley Discoveries, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioMed Valley Discoveries, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}